



Advancing Cancer Diagnosis

Improving patient outcomes while lowering health care costs

Forward looking statements

This presentation is confidential and the information herein may not be copied, modified, reproduced, redistributed, divulged or passed on, directly or indirectly, and you may use (including to trade on the basis of) any information herein.

This presentation is for informational purposes only. This document does not constitute an offer or solicitation to sell securities in any jurisdiction. It does not purport to contain all of the information that may be relevant to you.

Certain information contained in this presentation may be derived from information provided by industry sources. OncoCyte believes such information is accurate and that the sources from which it has been obtained are reliable. However, OncoCyte cannot guarantee the accuracy of, and has not independently verified, such information.

This presentation contains forward-looking statements that are based on OncoCyte's current understanding, expectations, and assumptions, which OncoCyte believes to be reasonable. These statements involve inherent risks and uncertainties, including those relating to the development and/or commercialization of potential diagnostic tests or products, the results of clinical trials or regulatory approvals, the capacity of third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need and ability to obtain future capital, maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients' use of any diagnostic tests commercialized. Actual results may differ materially from the results anticipated in these forward-looking statements. Please refer to the "Risk Factors" and other cautionary statements in OncoCyte's Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as required by law.


Except as otherwise indicated, this presentation speaks as of the date hereof.

Investment Highlights

- **Oncology diagnostics company targeting lung cancer – highest mortality rate**
- **DetermaVu™ lung test can reduce the number of expensive, risky, unnecessary biopsies, saving lives while lowering costs**
- **Compelling value proposition for physicians, patients, and payers**
- **Very large Total Addressable Market with high margin potential**
- **Rapid pathway to key results (Q4 2018) and commercialization (2H 2019)**

Advancing the Standard of Cancer Diagnosis

IP Protected gene expression classifier with binary call




Lung Cancer: Highest Mortality Rate

234,030

New diagnoses

154,050


Deaths



Annual Cancer Deaths

Source: American Cancer Society, Cancer Facts & Figures, 2018 (all figures annual)

Lung is One of Largest US Market Opportunities



Initial use


400,000–600,000 Patients with large nodules

Expanded use

1.4 Million Patients with medium to large nodules



Detecting Lung Cancer Early is Critical

Lung cancer is typically diagnosed in Stage IV, resulting in grim 5-year survival





But detection in Stage I gives 5-year survival comparable to other major cancers

Lung Cancer Detection Process



10 – 15M smokers should get annual Low Dose CT scans

If medium/large nodules are found, biopsy carried out



Lung Biopsies are Risky and Expensive

- **Lung biopsies are much riskier than other cancer biopsies**
 - Up to 1% result in death
 - Up to 20% result in serious complications
- **Mean U.S. cost is \$14,634 per biopsy**
 - Average cost of a lung biopsy with complications is \$37,745

For an average patient, a lung biopsy has a higher likelihood of leading to a serious complication than of confirming lung cancer

DetermaVu™ is Designed to Reduce Biopsies

Potential for*:

- 165,000 to 350,000 fewer procedures
- 25,000 to 55,000 fewer hospitalizations
- 2,000 to 5,000 lives saved
- Over \$4B annual U.S. cost savings

** Annual estimates; at 65% specificity*

Test Accuracy Exceeds Physician Requirements


Physicians require

>85% Sensitivity
>35% Specificity

Superior accuracy


DetermaVu

95% Sensitivity
73% Specificity



*This data from Vachani, A et al. American Thoracic Society and CHEST 2017, 299 patient clinical study
Performance on new assay and algorithm not available until completion of R&D Validation study*

Strong Physician Interest in DetermaVu™



Reasons physicians rated DetermaVu™ highly:

- Useful for smaller nodules with high-risk factors
- Provides additional accuracy and benefit
- Avoids unnecessary biopsies
- Non-invasive blood test
- Provides clinical utility

Results of (30) in-depth, clinician interviews fielded in September/October 2015.

Question asks: On a scale from 1-10 where 10 is very interested, how interested would you be in utilizing Test X?

Near-Term Milestones to Commercialization



Key milestones:

- Critical data Q4 2018
- Commercialization in 2H 2019

R&D Validation Data in Q4

- Study results should be indicative of final test performance
- Physicians require a minimum of 35% specificity with 85% sensitivity (market survey)
- At 65% specificity, annual potential for:
 - 165,000 to 350,000 fewer procedures
 - 25,000 to 55,000 fewer hospitalizations
 - 2,000 to 5,000 lives saved
 - Over \$4B annual U.S. cost savings
- R&D Validation will give specificity findings accurate to about +/- 8%

Capital-Efficient Commercialization Plan

- Capital on hand is sufficient to reach commercialization
- Efficient and focused sales and marketing plan
 - Low number of chest physicians, can be covered with a small specialty sales force
- Targeting both high gross margin and high net margin

Commercialization Strategy Addresses All Key Stakeholders

Physicians

- Determinate diagnosis
- High accuracy
- Reduce unnecessary biopsies

Patients

- Earlier diagnosis
- Improved outcomes
- Reduce anxiety over indeterminate findings

Payers

- Improved health outcomes
- Fewer unnecessary procedures
- Reduce overall costs

Benefits

Payers View DetermaVu™ Very Favorably

- Previewed intended use and clinical development plan with medical directors from 10 public and commercial payers
 - Included: Medicare, private Medicaid plans, United Healthcare, Aetna, Cigna, Anthem, and Humana
 - 77M covered lives
- All recognized the large unmet medical need addressed by DetermaVu
- Expressed strong support for DetermaVu's clinical development plan, saying it was robust and addressed appropriate clinical endpoints
- Indicated high level of interest in giving DetermaVu a positive coverage policy if it meets clinical endpoints of the planned studies

Extensive Leadership Experience

Management

William Annett	President, Chief Executive Officer and Board Member
Al Parker	Chief Operating Officer
Mitch Levine	Chief Financial Officer
Lyndal Hesterberg, PhD	SVP, Research and Development
William Haack	VP, Market Access and Business Operations

Board of Directors

Cavan Redmond	Chairman
Ronnie Andrews, Jr.	Board member
Andy Arno	Board member
Andrew Last	Board member
Adi Mohanty	Board member
Alfred Kingsley	Board member

Genentech

Pfizer

ThermoFisher
SCIENTIFIC

Wyeth
Pharmaceuticals

life
technologies

CRESCENDO
BIOSCIENCE
COMPANY

affymetrix

accenture

Genomic Health™

INVITAE

INTREXON®

CLARIENT
A GE Healthcare Company

WebMD®

OncoCyte™

Financial Summary

Ticker / exchange	OCX (NYSE American)
Recent close (8/28)	\$2.25
Shares outstanding	40.7mn
Market cap	~\$91mn
52-week range	\$1.10-\$7.64
Average daily trading volume	~100,000
Cash*	\$10.3mn (6/30/18)
<i>*Cash excludes \$3.3mn (net) raised in July via registered direct equity offering led by management and the Board</i>	
Covering research analysts	3*

* Benchmark (Bruce D. Jackson), Chardan Capital Markets (Keay Nakae, CFA), Janney Capital Markets (Paul Knight, CFA)

Investment Highlights

- **Oncology diagnostics company targeting lung cancer – highest mortality rate**
- **DetermaVu™ lung test can reduce the number of expensive, risky, unnecessary biopsies, saving lives while lowering costs**
- **Compelling value proposition for physicians, patients, and payers**
- **Very large Total Addressable Market with high margin potential**
- **Rapid pathway to key results (Q4 2018) and commercialization (2H 2019)**

Advancing Cancer Diagnosis

Improving patient outcomes while lowering health care costs



September 2018


NYSE AMERICAN: **OCX**

Appendix



NYSE AMERICAN: **OCX**


Cancer Diagnostic Continuum



Lung Cancer: the Largest Margin Opportunity

PRODUCT CONTRIBUTION OPPORTUNITY


(\$ million)



Probability of false positive test under current standard of care
(leading to unnecessary and expensive follow-up procedures)

DetermaVu™ is Designed to Reduce Unnecessary Biopsies

- 165,000 to 350,000 fewer procedures
- 25,000 to 55,000 fewer hospitalizations
- 2,000 to 5,000 lives saved



Intended use – Diagnostic test first launch, Lung-RADS 3&4

Assumptions: 15M patients screened, 13% positive results, molecular diagnostic with 65% specificity (OncoCyte test may have higher or lower specificity); all Lung RADS 3-4 referred to downstream procedures including repeat LDCTs, PET scans, bronchoscopies, surgical biopsies, with 15% complications and associated hospitalization costs. 65% physician compliance with test results. Cost offsets does not reflect cost of diagnostic. Based on average cost of lung biopsy of \$15,000, compared to \$3,500 for lung assay.

Validation Pathway for DetermaVu™



R&D Validation

- Confirms algorithm performance on a blinded sample set in an R&D setting

Analytical Validation

- Establishes the performance characteristics of the assay system to be validated in the CLIA laboratory

CLIA Validation

- Confirms that the assay has been successfully transferred to the CLIA laboratory


Clinical Validation

- Establishes the product performance claims in an independent, blinded data set

Clinical Utility

- Demonstrates a net improvement in patient outcomes or similar outcomes at a lower price

CLIA Regulatory Pathway in Place




- CLIA offers the quickest and least-risk path to commercial availability
- For our tests, FDA offers no commercial advantages, either for adoption or reimbursement
- OncoCyte's laboratory received CA CLIA certification August 2017

Reimbursement is Driven by Strong Clinical Trial Results

- Strong clinical validation and utility studies are key to coverage
- Planning for a “gold standard” Clinical Utility Study - randomized, prospective
- OncoCyte’s strategy is to provide the highest level of evidence to increase probability of both Medicare and private payer coverage

Robust clinical trial evidence plan will drive payer reimbursement

Valuation Driven by Market Opportunity and Reimbursement



Market capitalizations as of 8/30